Company: INMB
Filing Date: 2025-04-21
Form Type: DEF 14A
Source: 0001213900-25-033742
Chunk: 35

Company: Inmune Bio, Inc.
Filing Date: 2025-04-21
Form: DEF 14A
Chunk 35
---
 Agreements The Company and David Moss have entered into an employment agreement, beginning January 1, 2021, pursuant to which Mr. Moss is serving as our chief financial officer. Mr. Moss is paid a salary of $408,722 per annum. Mr. Moss is eligible for an annual discretionary bonus with a target amount of 40% of his then current base salary as determined by the Board of Directors and/or compensation committee in its discretion based upon the achievement of corporate and/or individual objectives that are determined in the sole discretion of the Board of Directors. Pursuant to the employment agreement if Mr. Moss is terminated without cause, or if he terminates his employment for good reason, (as those terms are defined in the employment agreement) the Company will be required to pay him the equivalent of 18 months of his base salary in effect as of the separation date. The Company and Raymond Tesi, M.D., have entered into an employment agreement, dated January 1, 2021, pursuant to which Dr. Tesi is serving as the Company’s chief executive officer and president. Dr. Tesi is paid a salary of $518,018 per annum. Dr. Tesi is eligible for an annual discretionary bonus with a target amount of 55% of his then current base salary as determined by the Board of Directors and/or compensation committee in its discretion based upon the achievement of corporate and/or individual objectives that are determined in the sole discretion of the Board of Directors. Pursuant to the employment agreement if Dr. Tesi is terminated without cause, or if he terminates his employment for good reason, (as those terms are defined in the employment agreement) the Company will be required to pay him the equivalent of 18 months of his base salary in effect as of the separation date. Consulting Agreement The Company and Mark Lowdell, PhD, have entered into a consulting agreement, dated May 1, 2024, pursuant to which Dr. Lowdell is serving as our Chief Scientific Officer. Dr. Lowdell was paid $246,692 in consulting fees during 2024. Securities Authorized for Issuance Under Equity Compensation Plans

25

OUTSTANDING EQUITY AWARDS AT FISCAL YEAR-END The following table summarizes the total outstanding equity awards as of December 31, 2024, for each Named Executive Officer:

| Name                  
 Number of             
 Securities            
 Underlying            
 Unexercised           
 Options (#)           
 Exercisable           |     | Grant Date    
 Number of     
 Securities    
 Under